Clinical Trial Update: A Study of Adalimumab When Added to Inadequate Standard Anti-rheumatic Therapy in Patients With Active Rheumatoid Arthritis [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluated adding adalimumab to inadequate standard anti-rheumatic therapy in patients with active rheumatoid arthritis; results were posted in 2…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Adalimumab (Humira) (adalimumab)

Snippet

Sponsor: Abbott | Conditions: Rheumatoid Arthritis | Phase 3 | Status: COMPLETED | Results posted: 2011-03-24